Norway-based Nordic Nanovector ASA, a clinical-stage oncology company, has appointed Renee Tannenbaum to its board. Dr Tannenbaum was previously an executive at AbbVie Inc and prior to that held senior positions at Novartis, Bristol-Myers Squibb Co and Merck & Co Inc. She holds a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences and an MBA from Temple University.
Also joining the board is the oncology expert Jean-Pierre Bizzari. Dr Bizzari was involved in the clinical development of cancer products at Celgene Corp, Rhône-Poulenc and Sanofi-Aventis. He currently is a member of the scientific advisory board of the French National Cancer Institute.
Nordic Nanovector announced the appointments on 23 May 2016.
Copyright 2016 Evernow Publishing Ltd